Presented by: Barbri
About the Course
The direct-to-consumer (DTC) prescription drug market is expanding rapidly as manufacturers explore new ways to improve patient access and respond to evolving pricing and market pressures. At the same time, these programs raise complex legal and regulatory questions involving the federal Anti-Kickback Statute (AKS), government enforcement priorities, payer relationships, pharmacy operations, and manufacturer compliance obligations. Join Jesse Dresser of Frier Levitt and Joseph Metro of Reed Smith for a timely discussion of the latest HHS Office of Inspector General (HHS-OIG) guidance and the legal considerations shaping today’s DTC drug models.
During this program, attendees will:
Attendees will gain practical insights into emerging DTC business models, the implications of recent HHS-OIG guidance, unresolved compliance risks, and best practices for developing and operating compliant DTC programs. The program is designed for manufacturers, pharmacies, healthcare providers, and other industry stakeholders navigating this rapidly evolving regulatory landscape.
